(DNLI) Denali Therapeutics - Ratings and Ratios
Alzheimer, Parkinson, ALS, Lysosomal Storage
DNLI EPS (Earnings per Share)
DNLI Revenue
Description: DNLI Denali Therapeutics
Denali Therapeutics Inc (NASDAQ:DNLI) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock is classified as a common stock and is of US origin.
To assess the companys financial health, we can look at its market capitalization, which stands at approximately $1.955 billion. The absence of a price-to-earnings (P/E) ratio, both current and forward, suggests that the company is currently not profitable, which is not uncommon for companies in the biotechnology sector that are often in the development phase. The return on equity (RoE) is negative at -35.90%, indicating that the company is not generating profits from shareholders equity.
Key economic drivers for Denali Therapeutics include the success of its drug pipeline, particularly in the treatment of neurodegenerative diseases, and the ability to secure funding or partnerships to support its research and development activities. Key performance indicators (KPIs) to watch include the progress of its clinical trials, regulatory approvals, and the companys cash burn rate, which will be crucial in determining its ability to continue operations without additional capital infusion.
From a trading perspective, the stocks volatility, as indicated by its average true range (ATR) and beta, suggests that it is relatively sensitive to market movements, with a beta of 1.328 indicating that it is more volatile than the overall market. Investors should also monitor the companys cash position and funding requirements to assess the risk of dilution or financial distress.
The quarterly tax provision is an important aspect to analyze as it can provide insights into the companys financial performance and tax obligations. A thorough examination of this provision can reveal the companys effective tax rate, any tax loss carryforwards, and the impact of tax on its net income or loss.
DNLI Stock Overview
| Market Cap in USD | 2,255m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-12-08 |
DNLI Stock Ratings
| Growth Rating | -73.7% |
| Fundamental | 26.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -47.4% |
| Analyst Rating | 4.79 of 5 |
DNLI Dividends
Currently no dividends paidDNLI Growth Ratios
| Growth Correlation 3m | 36.5% |
| Growth Correlation 12m | -70.5% |
| Growth Correlation 5y | -89.8% |
| CAGR 5y | -16.35% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.25 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.49 |
| Sharpe Ratio 12m | -0.58 |
| Alpha | -57.41 |
| Beta | 1.294 |
| Volatility | 55.58% |
| Current Volume | 1365.8k |
| Average Volume 20d | 2092.3k |
| Stop Loss | 15.6 (-6.4%) |
| Signal | -0.12 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA -4.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 (>3.0%) and CFO -349.6m > Net Income -479.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (171.4m) change vs 12m ago 1.55% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 22.00%; Δ -22.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.94 (EBITDA TTM -511.6m / Interest Expense TTM -43.8m) >= 6 (WARN >= 3) |
Altman Z'' -16.44
| (A) 0.72 = (Total Current Assets 934.7m - Total Current Liabilities 91.1m) / Total Assets 1.17b |
| (B) -1.54 = Retained Earnings (Balance) -1.80b / Total Assets 1.17b |
| warn (B) unusual magnitude: -1.54 — check mapping/units |
| (C) -0.39 = EBIT TTM -522.7m / Avg Total Assets 1.33b |
| (D) -12.88 = Book Value of Equity -1.79b / Total Liabilities 139.2m |
| Total Rating: -16.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.28
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -26.24% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda 0.19 = 2.47 |
| 6. ROIC - WACC (= -55.99)% = -12.50 |
| 7. RoE -40.79% = -2.50 |
| 8. Rev. Trend -43.79% = -3.28 |
| 9. EPS Trend -8.23% = -0.41 |
What is the price of DNLI shares?
Over the past week, the price has changed by +8.39%, over one month by +27.57%, over three months by +14.66% and over the past year by -39.24%.
Is Denali Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DNLI is around 12.04 USD . This means that DNLI is currently overvalued and has a potential downside of -27.73%.
Is DNLI a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DNLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.6 | 89.7% |
| Analysts Target Price | 31.6 | 89.7% |
| ValueRay Target Price | 13.8 | -17.2% |
Last update: 2025-10-06 02:04
DNLI Fundamental Data Overview
P/S = 3643.6484
P/B = 2.1639
Beta = 1.294
Revenue TTM = 0.0 USD
EBIT TTM = -522.7m USD
EBITDA TTM = -511.6m USD
Long Term Debt = 46.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.87m USD (from shortTermDebt, last quarter)
Debt = 46.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -94.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.40b USD (2.25b + Debt 46.6m - CCE 899.0m)
Interest Coverage Ratio = -11.94 (Ebit TTM -522.7m / Interest Expense TTM -43.8m)
FCF Yield = -26.24% (FCF TTM -368.0m / Enterprise Value 1.40b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.04m) / Revenue TTM)
Tobins Q-Ratio = 1.20 (Enterprise Value 1.40b / Total Assets 1.17b)
Interest Expense / Debt = 45.28% (Interest Expense 21.1m / Debt 46.6m)
Taxrate = -0.02% (negative due to tax credits) (68.0k / -422.7m)
NOPAT = -522.8m (EBIT -522.7m * (1 - -0.02%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.27 (Total Current Assets 934.7m / Total Current Liabilities 91.1m)
Debt / Equity = 0.05 (Debt 46.6m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -94.6m / EBITDA -511.6m)
Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -94.6m / FCF TTM -368.0m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = -41.08% (Net Income -479.0m / Total Assets 1.17b)
RoE = -40.79% (Net Income TTM -479.0m / Total Stockholder Equity 1.17b)
RoCE = -42.81% (EBIT -522.7m / Capital Employed (Equity 1.17b + L.T.Debt 46.6m))
RoIC = -44.51% (negative operating profit) (NOPAT -522.8m / Invested Capital 1.17b)
WACC = 11.48% (E(2.25b)/V(2.30b) * Re(10.78%) + D(46.6m)/V(2.30b) * Rd(45.28%) * (1-Tc(-0.00)))
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.36%
Fair Price DCF = unknown (Cash Flow -368.0m)
EPS Correlation: -8.23 | EPS CAGR: 80.68% | SUE: 4.0 | # QB: 1
Revenue Correlation: -43.79 | Revenue CAGR: -0.42% | SUE: -0.01 | # QB: 0
Additional Sources for DNLI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle